Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$5.29B+21.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter J. Arduini
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 54,000
- Beta
- 0.82
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.66
Financials
Revenue
$5.29B+21.8%Net Income
$573.00M-1.4%EBITDA
$953.00M+10.0%Free Cash Flow
$-617.00M-232.7%EPS (diluted)
$1.24-3.0%Shares Outstanding (diluted)
454.00M-0.2%Operating Expenses
$1.44BCash & Debt
$2.10BReturn of Capital
$216.00MRevenue by Segment (annual)
$15.23BDividend per Share
$0.04Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $20.63B | $2.08B | $4.56 |
| 2024 | $19.67B | $1.99B | $4.37 |
| 2023 | $19.55B | $1.57B | $3.04 |
| 2022 | $18.34B | $1.92B | $4.22 |
| 2021 | $17.59B | $2.25B | $4.90 |
| 2020 | $17.16B | $13.85B | $4.41 |
| 2019 | $16.63B | $1.52B | $3.35 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GEHC's reported EPS growth of 5.3% a year over 6 years.
- EPS in 5 years
- $5.91
- Implied price
- $106.38
- Return from $64.29
- 10.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $52.89 — -17.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -4.7% | -7.7% | -3.5% | 0.1% | 3.2% | 6.0% |
| 0.3% | -2.9% | 1.6% | 5.3% | 8.6% | 11.6% |
| 5.3% | 2.0% | 6.6% | 10.6% | 14.1% | 17.1% |
| 10.3% | 6.8% | 11.7% | 15.8% | 19.5% | 22.7% |
| 15.3% | 11.7% | 16.8% | 21.1% | 24.9% | 28.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
58-16.67%Social Signal Score
Mentions (34)
- Newsglobenewswire.com·1d ago·Negative
GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
View source ↗ - Newsbarrons.com·1d ago·Neutral
GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area.
View source ↗ - Newsglobenewswire.com·3d ago·Negative
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newszacks.com·3d ago·Neutral
GEHC vs. SYK: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
View source ↗ - Newszacks.com·5d ago·Positive
GE HealthCare (GEHC) Upgraded to Buy: Here's Why GE HealthCare (GEHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·7d ago·Positive
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now GEHC's record backlog, strong orders and AI-enabled innovations offer growth potential, while inflation and China remain key risks.
View source ↗ - News (RSS)seekingalpha·13d ago·Neutral
GE HealthCare Technologies boosts dividend by 14.3% to $0.04 a share
View source ↗ - Newsbusinesswire.com·13d ago·Negative
GE HealthCare announces cash dividend increase for third quarter of 2026 CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an increase of 14% from the previous quarter. The dividend will be payable on November 13, 2026, to all shareholders of record as of October 23, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthca…
View source ↗ - Newsbusinesswire.com·13d ago·Neutral
GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company, to its Board of Directors, effective January 4, 2027. Mr. Desroches brings more than 30 years of leadership experience across finance, governance, and large-scale technology and digital transformat…
View source ↗ - News (RSS)seekingalpha·16d ago·Neutral
Key deals this week: SPGI, PSO, GEHC, and more
View source ↗ - Newsglobenewswire.com·19d ago·Negative
GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
View source ↗ - News (RSS)yahoo·19d ago·Neutral
GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newszacks.com·19d ago·Neutral
GEHC or SYK: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Products sector might want to consider either GE HealthCare Technologies (GEHC) or Stryker (SYK). But which of these two stocks is more attractive to value investors?
View source ↗ - Newszacks.com·19d ago·Negative
GEHC Launches CareIntellect AI Tool to Optimize Hospital Operations GE HealthCare launches an AI-powered SaaS tool that predicts hospital capacity challenges up to 72 hours ahead and recommends actions to ease bottlenecks.
View source ↗ - Newszacks.com·19d ago·Positive
Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsreuters.com·23d ago·Positive
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports GE HealthCare Technologies is in talks over a possible $1 billion deal to buy radiopharmaceutical developer Sofie Biosciences, the Financial Times reported on Sunday citing people familiar with the matter.
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
GE HealthCare Technologies Inc. (GEHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
GE HealthCare Technologies Inc. (GEHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript GE HealthCare Technologies Inc. (GEHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·26d ago·Negative
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance GEHC moves StarGuide GX closer to the U.S. market with an FDA 510(k) submission, advancing its next-generation molecular imaging push.
View source ↗ - Newszacks.com·33d ago·Positive
GEHC Wins CE Mark for Photonova Spectra, Expands International Reach GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.
View source ↗ - News (RSS)yahoo·34d ago·Neutral
GE HealthCare’s (GEHC) Latest Scanner Breakthrough Meets A Mixed Market
View source ↗ - Newszacks.com·35d ago·Negative
GEHC vs. HAE: Which Stock Is the Better Value Option? Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
View source ↗ - Newszacks.com·35d ago·Neutral
GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems GEHC expands its Vivid cardiovascular ultrasound portfolio with three systems featuring AI tools and cSound imaging for varied care settings.
View source ↗ - Newsbusinesswire.com·39d ago·Neutral
GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus.
View source ↗ - Newsbusinesswire.com·41d ago·Neutral
GE HealthCare management to present at upcoming investor conference CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference: Wells Fargo 21st Annual Health Conference – Wednesday, September 9, 2026 at 10:15 am ET/9:15am CT A webcast for the event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events at the date and time listed above. About GE He…
View source ↗ - Newszacks.com·42d ago·Neutral
GEHC Q2 Orders Surge 11.1% as Record Backlog Builds 2027 Visibility GEHC's 11.1% order growth and record $23.9B backlog improve revenue visibility, but PCS execution and inflation remain key constraints.
View source ↗ - Newszacks.com·42d ago·Neutral
Is GEHC a Buy Now as Growth Improves but Execution Risks Persist? GEHC's valuation discount and growth in imaging and diagnostics support the case, but PCS weakness, inflation and debt keep execution risks elevated.
View source ↗ - Newszacks.com·42d ago·Positive
Here's Why You Should Add GEHC Stock to Your Portfolio for Now GE HealthCare's record backlog, strong Pharmaceutical Diagnostics growth and AI innovation support its growth outlook despite margin pressures.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newszacks.com·53d ago·Neutral
GEHC or LMAT: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·54d ago·Positive
GE HealthCare (GEHC) Upgraded to Buy: Here's What You Should Know GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·55d ago·Positive
GE HealthCare Technologies (GEHC) Just Overtook the 200-Day Moving Average GE HealthCare Technologies (GEHC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GEHC broke through the 200-day moving average, which suggests a long-term bullish trend.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $1.20 per share
Typical surprise +8.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$1.13 vs $1.04beat
- Wed, Apr 29$0.99 vs $1.04miss
- Wed, Feb 4$1.44 vs $1.40beat
- Wed, Oct 29$1.07 vs $1.05beat
- Wed, Jul 30$1.06 vs $0.92beat
- Wed, Apr 30$1.01 vs $0.91beat
Estimates and results for GEHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GEHC officers and directors.
- Bought
- $6.4m
- Sold
- —
8 trades
0 trades
- Lobo Kevinbought
- Hochman Rodney Fbought
- Yang Watkin Phoebe L.bought
- Culp H Lawrence Jrbought
- Stromberg William Jbought
- Saccaro Jamesbought
- Jimenez Frank Rbought
- Arduini Peter Jbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (37d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (13d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (41d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2026 (8d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- Terri Sewellhouse · AL07 · disclosed Apr 21, 2026 (27d later)Sell$1,001 - $15,000
- Warren Davidsonhouse · OH08 · disclosed Mar 26, 2026 (3d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Austin Scotthouse · GA08 · disclosed Aug 13, 2025 (139d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (8d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 7, 2023 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (20d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.